COMPOSÉS INHIBITEURS À BASE DE THIOSEMICARBAZONE ET PROCÉDÉS DE TRAITEMENT DU CANCER

• 收藏
• 分享

专利权人:

Critical Outcome Technologies; Inc.

发明人:

申请号：

EP15184937.9

公开号：

EP3023426A1

申请日:

2009.07.17

申请国别(地区):

EP

年份:

2016

代理人:

摘要：

The present invention relates to a compound comprising Formula I or IA and an anti-cancer agent in combination, for use in treating a cancer in a mammal in need thereof, the cancer characterized by a KRAS mutation, by an EGFR mutation, and/or by over-expression of AKT2 and wherein the combination produces a synergistic therapeutic effect as compared to sole administration of either the anti-cancer agent or the compound.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/